Mesoblast sells Ryoncil, a cell therapy approved in the U.S. for children with steroid-refractory acute graft-versus-host disease, and is testing rexlemestrocel-L in chronic low back pain and heart failure.
Mesoblast's investment case combines growing Ryoncil sales with larger clinical and regulatory opportunities. Ryoncil is approved for pediatric steroid-refractory acute GVHD, and its adult registration trial is enrolling. Rexlemestrocel-L's back-pain Phase 3 treated 350 patients, with results expected in the second half of 2027. FDA has confirmed the LVAD gastrointestinal-bleeding BLA filing may proceed, with formal minutes pending. Cash of US$99 million and lower operating cash spend support execution, while pivotal results and filing completion remain central dependencies.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Back-pain Phase 3 confirms benefit
Does rexlemestrocel-L demonstrate durable pain reduction at 12 months versus control in MSB-DR004?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ryoncil grows; back-pain results and LVAD filing remain key
Ryoncil revenues fund the balance sheet while a Phase 3 back-pain readout — with 350 patients done — becomes the single value-defining binary
Ryoncil revenue funds the build while rexlemestrocel-L's fully enrolled CLBP Phase 3 is the make-or-break event for a blockbuster claim
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases, Neurology and pain, Liver and digestive diseases, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.